[{"id":"0c02cc4f-da25-44d0-b391-3f1638d91362","acronym":"AMPLIFY-NEOVAC","url":"https://clinicaltrials.gov/study/NCT03893903","created_at":"2021-01-18T19:10:49.432Z","updated_at":"2024-07-02T16:34:38.157Z","phase":"Phase 1","brief_title":"AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma","source_id_and_acronym":"NCT03893903 - AMPLIFY-NEOVAC","lead_sponsor":"German Cancer Research Center","biomarkers":" ATRX","pipe":" | ","alterations":" IDH1 R132","tags":["ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • IDH1R132H peptide vaccine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/19/2018","start_date":" 10/19/2018","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-05"},{"id":"82f2ff91-c9b2-437a-91b0-1a704c957940","acronym":"NOA-16","url":"https://clinicaltrials.gov/study/NCT02454634","created_at":"2021-01-18T11:46:29.017Z","updated_at":"2024-07-02T16:37:05.534Z","phase":"Phase 1","brief_title":"Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas","source_id_and_acronym":"NCT02454634 - NOA-16","lead_sponsor":"National Center for Tumor Diseases, Heidelberg","biomarkers":" IDH1 • IFNG • ATRX","pipe":" | ","alterations":" IDH1 R132H • IDH1 R132","tags":["IDH1 • IFNG • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1R132H peptide vaccine"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 09/19/2017","primary_completion_date":" 09/19/2017","study_txt":" Completion: 09/19/2017","study_completion_date":" 09/19/2017","last_update_posted":"2018-11-07"}]